{"id":"vegf","name":"VEGF / VEGFR","symbol":"VEGFA, KDR, FLT1, FLT4, PGF","route":"/targets/vegf/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12680","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000112715","uniprot":"https://www.uniprot.org/uniprotkb/P15692/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P15692","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1783","open-targets":"https://platform.opentargets.org/target/ENSG00000112715","civic":"https://civicdb.org/genes/7422/summary","oncokb":"https://www.oncokb.org/gene/VEGFA","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=VEGFA","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=VEGFA","depmap":"https://depmap.org/portal/gene/VEGFA?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000112715-VEGFA","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/7422","omim":"https://www.omim.org/entry/192240"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6307","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000128052","uniprot":"https://www.uniprot.org/uniprotkb/P35968/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P35968","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL279","open-targets":"https://platform.opentargets.org/target/ENSG00000128052","civic":"https://civicdb.org/genes/3791/summary","oncokb":"https://www.oncokb.org/gene/KDR","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=KDR","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=KDR","depmap":"https://depmap.org/portal/gene/KDR?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000128052-KDR","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/3791","omim":"https://www.omim.org/entry/191306"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3763","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102755","uniprot":"https://www.uniprot.org/uniprotkb/P17948/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P17948","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1868","open-targets":"https://platform.opentargets.org/target/ENSG00000102755","civic":"https://civicdb.org/genes/2321/summary","oncokb":"https://www.oncokb.org/gene/FLT1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FLT1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=FLT1","depmap":"https://depmap.org/portal/gene/FLT1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000102755-FLT1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2321","omim":"https://www.omim.org/entry/165070"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3767","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000037280","uniprot":"https://www.uniprot.org/uniprotkb/P35916/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P35916","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1955","open-targets":"https://platform.opentargets.org/target/ENSG00000037280","civic":"https://civicdb.org/genes/2324/summary","oncokb":"https://www.oncokb.org/gene/FLT4","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FLT4","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=FLT4","depmap":"https://depmap.org/portal/gene/FLT4?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000037280-FLT4","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2324","omim":"https://www.omim.org/entry/136352"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8893","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119630","uniprot":"https://www.uniprot.org/uniprotkb/P49763/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P49763","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1697671","open-targets":"https://platform.opentargets.org/target/ENSG00000119630","civic":"https://civicdb.org/genes/5228/summary","oncokb":"https://www.oncokb.org/gene/PGF","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PGF","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=PGF","depmap":"https://depmap.org/portal/gene/PGF?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000119630-PGF","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/5228","omim":"https://www.omim.org/entry/601121"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3763","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102755","uniprot":"https://www.uniprot.org/uniprotkb/P17948/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P17948","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1868","open-targets":"https://platform.opentargets.org/target/ENSG00000102755","civic":"https://civicdb.org/genes/2321/summary","oncokb":"https://www.oncokb.org/gene/FLT1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FLT1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=FLT1","depmap":"https://depmap.org/portal/gene/FLT1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000102755-FLT1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2321","omim":"https://www.omim.org/entry/165070"},{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3767","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000037280","uniprot":"https://www.uniprot.org/uniprotkb/P35916/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P35916","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1955","open-targets":"https://platform.opentargets.org/target/ENSG00000037280","civic":"https://civicdb.org/genes/2324/summary","oncokb":"https://www.oncokb.org/gene/FLT4","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FLT4","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=FLT4","depmap":"https://depmap.org/portal/gene/FLT4?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000037280-FLT4","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2324","omim":"https://www.omim.org/entry/136352"}],"products":[{"id":"ai-081","name":"AI-081","status":"phase-2","modality":"bispecific antibody","route":"/drugs/ai-081/"},{"id":"anlotinib","name":"Anlotinib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, KIT)","route":"/drugs/anlotinib/"},{"id":"axitinib","name":"Axitinib","status":"approved","modality":"Small-molecule kinase inhibitor (VEGFR)","route":"/drugs/axitinib/"},{"id":"bevacizumab","name":"Bevacizumab","status":"approved","modality":"Monoclonal antibody (anti-VEGF)","route":"/drugs/bevacizumab/"},{"id":"bevacizumab-glioma","name":"Bevacizumab (glioblastoma use)","status":"approved","modality":"Monoclonal antibody (anti-VEGF)","route":"/drugs/bevacizumab-glioma/"},{"id":"cabozantinib","name":"Cabozantinib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (MET, VEGFR2, AXL, RET)","route":"/drugs/cabozantinib/"},{"id":"camrelizumab-rivoceranib","name":"Camrelizumab + rivoceranib","status":"approved","modality":"PD-1 antibody + oral VEGFR2 inhibitor","route":"/drugs/camrelizumab-rivoceranib/"},{"id":"cediranib","name":"Cediranib","status":"phase-2","modality":"Oral VEGFR 1-3 tyrosine kinase inhibitor","route":"/drugs/cediranib/"},{"id":"chiauranib","name":"Chiauranib","status":"phase-3","modality":"small molecule","route":"/drugs/chiauranib/"},{"id":"donafenib","name":"Donafenib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (deuterated sorafenib)","route":"/drugs/donafenib/"},{"id":"fruquintinib","name":"Fruquintinib","status":"approved","modality":"Small-molecule kinase inhibitor (VEGFR1-3)","route":"/drugs/fruquintinib/"},{"id":"ivonescimab","name":"Ivonescimab","status":"approved","modality":"Bispecific antibody (PD-1×VEGF)","route":"/drugs/ivonescimab/"},{"id":"lenvatinib","name":"Lenvatinib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (VEGFR, FGFR, PDGFR, RET, KIT)","route":"/drugs/lenvatinib/"},{"id":"nintedanib","name":"Nintedanib","status":"approved","modality":"Small-molecule kinase inhibitor (VEGFR/FGFR/PDGFR)","route":"/drugs/nintedanib/"},{"id":"pazopanib","name":"Pazopanib","status":"approved","modality":"Small-molecule kinase inhibitor (VEGFR/PDGFR/KIT)","route":"/drugs/pazopanib/"},{"id":"pm8002","name":"PM8002","status":"phase-3","modality":"bispecific antibody","route":"/drugs/pm8002/"},{"id":"propranolol-hemangeol","name":"Propranolol (Hemangeol)","status":"established","modality":"Small-molecule non-selective beta-adrenergic blocker, oral solution","route":"/drugs/propranolol-hemangeol/"},{"id":"ramucirumab","name":"Ramucirumab","status":"approved","modality":"Monoclonal antibody (anti-VEGFR2)","route":"/drugs/ramucirumab/"},{"id":"regorafenib","name":"Regorafenib","status":"approved","modality":"Small-molecule multi-kinase inhibitor","route":"/drugs/regorafenib/"},{"id":"rivoceranib","name":"Rivoceranib (apatinib)","status":"approved","modality":"Small-molecule VEGFR2 TKI","route":"/drugs/rivoceranib/"},{"id":"sorafenib","name":"Sorafenib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, RAF)","route":"/drugs/sorafenib/"},{"id":"sunitinib","name":"Sunitinib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, KIT)","route":"/drugs/sunitinib/"},{"id":"surufatinib","name":"Surufatinib","status":"approved","modality":"Oral VEGFR, FGFR1 and CSF1R tyrosine kinase inhibitor","route":"/drugs/surufatinib/"},{"id":"tivozanib","name":"Tivozanib","status":"approved","modality":"Small-molecule kinase inhibitor (VEGFR)","route":"/drugs/tivozanib/"},{"id":"tovecimig","name":"Tovecimig","status":"phase-3","modality":"bispecific antibody","route":"/drugs/tovecimig/"},{"id":"vandetanib","name":"Vandetanib","status":"approved","modality":"Small-molecule kinase inhibitor (RET, VEGFR, EGFR)","route":"/drugs/vandetanib/"},{"id":"vorolanib","name":"Vorolanib","status":"approved","modality":"Oral multi-target VEGFR and PDGFR tyrosine kinase inhibitor","route":"/drugs/vorolanib/"},{"id":"zanzalintinib","name":"Zanzalintinib","status":"phase-3","modality":"small molecule","route":"/drugs/zanzalintinib/"},{"id":"ziv-aflibercept","name":"Ziv-aflibercept","status":"approved","modality":"Recombinant fusion protein (VEGF ligand trap)","route":"/drugs/ziv-aflibercept/"}],"trials":[{"id":"mountaineer-03","name":"MOUNTAINEER-03","nct":"NCT05253651","phase":"3","status":"recruiting"},{"id":"nct04194775","name":"A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma","nct":"NCT04194775","phase":"3","status":"active"},{"id":"clarity-gastric01","name":"CLARITY-Gastric 01","nct":"NCT06346392","phase":"3","status":"positive"},{"id":"emerald-3","name":"EMERALD-3","nct":"NCT05301842","phase":"3","status":"positive"},{"id":"harmoni-3","name":"HARMONi-3","nct":"NCT05899608","phase":"3","status":"mixed"},{"id":"nct04586231","name":"LITESPARK-011","nct":"NCT04586231","phase":"3","status":"positive"},{"id":"litespark-012","name":"LITESPARK-012","nct":"NCT04736706","phase":"3","status":"negative"},{"id":"nct04094688","name":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","nct":"NCT04094688","phase":"3","status":"active"},{"id":"nct03829462","name":"Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients","nct":"NCT03829462","phase":"3","status":"active"},{"id":"destiny-gastric04","name":"DESTINY-Gastric04","nct":"NCT04704934","phase":"3","status":"positive"},{"id":"keynote-b96","name":"KEYNOTE-B96 / ENGOT-ov65","nct":"NCT05116189","phase":"3","status":"positive"},{"id":"nct04446117","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","nct":"NCT04446117","phase":"3","status":"active"},{"id":"nct03755791","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece","nct":"NCT03755791","phase":"3","status":"active"},{"id":"nct03673501","name":"A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib","nct":"NCT03673501","phase":"3","status":"active"},{"id":"cabinet","name":"CABINET (Alliance A021602)","nct":"NCT03375320","phase":"3","status":"positive"},{"id":"compassion-16","name":"COMPASSION-16 / AK104-303","nct":"NCT04982237","phase":"3","status":"positive"},{"id":"harmoni-2","name":"HARMONi-2","nct":"NCT05499390","phase":"3","status":"positive"},{"id":"harmoni-a","name":"HARMONi-A","nct":"NCT05184712","phase":"3","status":"positive"},{"id":"leap-012","name":"LEAP-012","nct":"NCT04246177","phase":"3","status":"mixed"},{"id":"tinivo-2","name":"TiNivo-2","nct":"NCT04987203","phase":"3","status":"negative"},{"id":"nct03690388","name":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va","nct":"NCT03690388","phase":"3","status":"active"},{"id":"beatcc","name":"BEATcc / ENGOT-Cx10 / GOG-3030","nct":"NCT03556839","phase":"3","status":"positive"},{"id":"cairo5","name":"CAIRO5","nct":"NCT02162563","phase":"3","status":"mixed"},{"id":"cares-310","name":"CARES-310","nct":"NCT03764293","phase":"3","status":"positive"},{"id":"contact-03","name":"CONTACT-03","nct":"NCT04338269","phase":"3","status":"negative"},{"id":"duo-o","name":"DUO-O / ENGOT-ov46","nct":"NCT03737643","phase":"3","status":"mixed"},{"id":"fresco-2","name":"FRESCO-2","nct":"NCT04322539","phase":"3","status":"positive"},{"id":"sunlight","name":"SUNLIGHT","nct":"NCT04737187","phase":"3","status":"positive"},{"id":"cosmic-313","name":"COSMIC-313","nct":"NCT03937219","phase":"3","status":"mixed"},{"id":"leap-002","name":"LEAP-002","nct":"NCT03713593","phase":"3","status":"negative"},{"id":"paradigm","name":"PARADIGM","nct":"NCT02394795","phase":"3","status":"positive"},{"id":"clear","name":"CLEAR (KEYNOTE-581)","nct":"NCT02811861","phase":"3","status":"positive"},{"id":"keynote-775","name":"KEYNOTE-775 / Study 309","nct":"NCT03517449","phase":"3","status":"positive"},{"id":"keynote-826","name":"KEYNOTE-826","nct":"NCT03635567","phase":"3","status":"positive"},{"id":"nct02411448","name":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RE","nct":"NCT02411448","phase":"3","status":"active"},{"id":"aaml1031","name":"AAML1031","nct":"NCT01371981","phase":"3","status":"mixed"},{"id":"checkmate-143","name":"CheckMate 143","nct":"NCT02017717","phase":"3","status":"negative"},{"id":"checkmate-9er","name":"CheckMate 9ER","nct":"NCT03141177","phase":"3","status":"positive"},{"id":"imbrave150","name":"IMbrave150","nct":"NCT03434379","phase":"3","status":"positive"},{"id":"sanet","name":"SANET-ep and SANET-p","nct":"NCT02588170","phase":"3","status":"positive"},{"id":"nct03091192","name":"Savolitinib vs. Sunitinib in MET-driven PRCC.","nct":"NCT03091192","phase":"3","status":"active"},{"id":"tribe2","name":"TRIBE2","nct":"NCT02339116","phase":"3","status":"positive"},{"id":"imblaze370","name":"IMblaze370","nct":"NCT02788279","phase":"3","status":"negative"},{"id":"keynote-426","name":"KEYNOTE-426","nct":"NCT02853331","phase":"3","status":"positive"},{"id":"paola-1","name":"PAOLA-1 / ENGOT-ov25","nct":"NCT02477644","phase":"3","status":"positive"},{"id":"nct03260894","name":"Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)","nct":"NCT03260894","phase":"3","status":"completed"},{"id":"reach-2","name":"REACH-2","nct":"NCT02435433","phase":"3","status":"positive"},{"id":"tappas","name":"TAPPAS","nct":"NCT02979899","phase":"3","status":"negative"},{"id":"carmena","name":"CARMENA","nct":"NCT00930033","phase":"3","status":"positive"},{"id":"celestial","name":"CELESTIAL","nct":"NCT01908426","phase":"3","status":"positive"},{"id":"checkmate-214","name":"CheckMate 214","nct":"NCT02231749","phase":"3","status":"positive"},{"id":"fresco","name":"FRESCO","nct":"NCT02314819","phase":"3","status":"positive"},{"id":"impower150","name":"IMpower150","nct":"NCT02366143","phase":"3","status":"positive"},{"id":"reflect","name":"REFLECT","nct":"NCT01761266","phase":"3","status":"positive"},{"id":"calgb-80405","name":"CALGB/SWOG 80405","nct":"NCT00265850","phase":"3","status":"mixed"},{"id":"resorce","name":"RESORCE","nct":"NCT01774344","phase":"3","status":"positive"},{"id":"sarah-sirvenib","name":"SARAH and SIRveNIB","nct":"NCT01482442","phase":"3","status":"negative"},{"id":"comet-1","name":"COMET-1","nct":"NCT01605227","phase":"3","status":"negative"},{"id":"nct00569127","name":"Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor","nct":"NCT00569127","phase":"3","status":"active"},{"id":"cairo3","name":"CAIRO3","nct":"NCT00442637","phase":"3","status":"positive"},{"id":"concur","name":"CONCUR","nct":"NCT01584830","phase":"3","status":"positive"},{"id":"raise","name":"RAISE","nct":"NCT01183780","phase":"3","status":"positive"},{"id":"select-lenvatinib","name":"SELECT","nct":"NCT01321554","phase":"3","status":"positive"},{"id":"aurelia","name":"AURELIA","nct":"NCT00976911","phase":"3","status":"positive"},{"id":"avaglio","name":"AVAglio","nct":"NCT00943826","phase":"3","status":"negative"},{"id":"lume-lung-1","name":"LUME-Lung 1","nct":"NCT00805194","phase":"3","status":"mixed"},{"id":"rainbow","name":"RAINBOW","nct":"NCT01170663","phase":"3","status":"positive"},{"id":"revel","name":"REVEL","nct":"NCT01168973","phase":"3","status":"positive"},{"id":"tribe","name":"TRIBE","nct":"NCT00719797","phase":"3","status":"positive"},{"id":"correct","name":"CORRECT","nct":"NCT01103323","phase":"3","status":"positive"},{"id":"decision-sorafenib","name":"DECISION","nct":"NCT00984282","phase":"3","status":"positive"},{"id":"grid","name":"GRID","nct":"NCT01271712","phase":"3","status":"positive"},{"id":"calgb-90401","name":"CALGB 90401","nct":"NCT00110214","phase":"3","status":"negative"},{"id":"nct00399035","name":"Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","nct":"NCT00399035","phase":"3","status":"completed"},{"id":"nct00777153","name":"Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma","nct":"NCT00777153","phase":"3","status":"completed"},{"id":"exam","name":"EXAM","nct":"NCT00704730","phase":"3","status":"positive"},{"id":"velour","name":"VELOUR","nct":"NCT00561470","phase":"3","status":"positive"},{"id":"zeta","name":"ZETA","nct":"NCT00410761","phase":"3","status":"positive"},{"id":"gog-0218-icon7","name":"GOG-0218 & ICON7 (bevacizumab)","nct":"NCT00262847","phase":"3","status":"mixed"},{"id":"crystal-fire3","name":"CRYSTAL & FIRE-3","nct":"NCT00154102","phase":"3","status":"positive"},{"id":"sharp","name":"SHARP","nct":"NCT00105443","phase":"3","status":"positive"},{"id":"avf2107g","name":"AVF2107g","phase":"3","status":"positive"},{"id":"nct07489495","name":"A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)","nct":"NCT07489495","phase":"3","status":"recruiting"},{"id":"nct07227402","name":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)","nct":"NCT07227402","phase":"3","status":"recruiting"},{"id":"nct07216703","name":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc","nct":"NCT07216703","phase":"3","status":"recruiting"},{"id":"nct07676162","name":"A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal","nct":"NCT07676162","phase":"3","status":"recruiting"},{"id":"nct06469879","name":"A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients","nct":"NCT06469879","phase":"3","status":"planned"},{"id":"nct07318558","name":"A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)","nct":"NCT07318558","phase":"3","status":"recruiting"},{"id":"nct06953999","name":"A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer","nct":"NCT06953999","phase":"3","status":"recruiting"},{"id":"nct06496971","name":"A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients","nct":"NCT06496971","phase":"3","status":"recruiting"},{"id":"nct04188145","name":"A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Meta","nct":"NCT04188145","phase":"3","status":"active"},{"id":"nct05654454","name":"A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer","nct":"NCT05654454","phase":"3","status":"recruiting"},{"id":"nct06048315","name":"A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs W","nct":"NCT06048315","phase":"3","status":"planned"},{"id":"nct07728955","name":"A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for","nct":"NCT07728955","phase":"3","status":"planned"},{"id":"nct07730489","name":"A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, F","nct":"NCT07730489","phase":"3","status":"planned"},{"id":"nct05904886","name":"A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell","nct":"NCT05904886","phase":"3","status":"active"},{"id":"nct03148418","name":"A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)","nct":"NCT03148418","phase":"3","status":"active"},{"id":"nct03303495","name":"A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC","nct":"NCT03303495","phase":"3","status":"recruiting"},{"id":"nct06371157","name":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat","nct":"NCT06371157","phase":"3","status":"recruiting"},{"id":"nct07010263","name":"A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor","nct":"NCT07010263","phase":"3","status":"recruiting"},{"id":"nct06750094","name":"A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy","nct":"NCT06750094","phase":"3","status":"recruiting"},{"id":"nct04854668","name":"A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Can","nct":"NCT04854668","phase":"3","status":"active"},{"id":"nct03729245","name":"A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)","nct":"NCT03729245","phase":"3"},{"id":"nct05899049","name":"A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study","nct":"NCT05899049","phase":"3","status":"active"},{"id":"nct04712643","name":"A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma","nct":"NCT04712643","phase":"3","status":"active"},{"id":"nct05320692","name":"A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma","nct":"NCT05320692","phase":"3","status":"active"},{"id":"nct06497985","name":"A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients","nct":"NCT06497985","phase":"3","status":"recruiting"},{"id":"nct07821684","name":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanc","nct":"NCT07821684","phase":"3","status":"planned"},{"id":"nct04639180","name":"A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recur","nct":"NCT04639180","phase":"3","status":"active"},{"id":"nct07361497","name":"A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell","nct":"NCT07361497","phase":"3","status":"recruiting"},{"id":"nct06824467","name":"A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl","nct":"NCT06824467","phase":"3","status":"recruiting"},{"id":"nct07361510","name":"A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P","nct":"NCT07361510","phase":"3","status":"recruiting"},{"id":"nct07286266","name":"A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","nct":"NCT07286266","phase":"3","status":"recruiting"},{"id":"nct03390686","name":"A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer ","nct":"NCT03390686","phase":"3","status":"active"},{"id":"nct05797467","name":"Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients","nct":"NCT05797467","phase":"3","status":"recruiting"},{"id":"nct06951503","name":"AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer","nct":"NCT06951503","phase":"3","status":"recruiting"},{"id":"nct05840016","name":"AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer","nct":"NCT05840016","phase":"3","status":"active"},{"id":"nct06767527","name":"AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer","nct":"NCT06767527","phase":"3","status":"recruiting"},{"id":"aldoxorubicin-phase-3-sts","name":"Aldoxorubicin versus investigator's choice in relapsed or refractory soft tissue sarcoma","nct":"NCT02049905","phase":"3","status":"negative"},{"id":"nct05112965","name":"An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)","nct":"NCT05112965","phase":"3","status":"active"},{"id":"nct00532194","name":"An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer","nct":"NCT00532194","phase":"3"},{"id":"nct05862337","name":"Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.","nct":"NCT05862337","phase":"3","status":"recruiting"},{"id":"nct07443397","name":"Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.","nct":"NCT07443397","phase":"3","status":"recruiting"},{"id":"nct03847428","name":"Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment","nct":"NCT03847428","phase":"3","status":"active"},{"id":"nct07481786","name":"Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases","nct":"NCT07481786","phase":"3","status":"recruiting"},{"id":"nct06566755","name":"Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer","nct":"NCT06566755","phase":"3","status":"recruiting"},{"id":"nct04921527","name":"Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer","nct":"NCT04921527","phase":"3","status":"recruiting"},{"id":"nct06767514","name":"Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1","nct":"NCT06767514","phase":"3","status":"recruiting"},{"id":"nct05171660","name":"Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer","nct":"NCT05171660","phase":"3","status":"active"},{"id":"nct07389265","name":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","nct":"NCT07389265","phase":"3","status":"recruiting"},{"id":"nct05059522","name":"Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing","nct":"NCT05059522","phase":"3","status":"active"},{"id":"nct05482516","name":"Evaluating Novel Therapies in ctDNA Positive GI Cancers","nct":"NCT05482516","phase":"3","status":"recruiting"},{"id":"nct07405164","name":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","nct":"NCT07405164","phase":"3","status":"recruiting"},{"id":"nct07235930","name":"Firstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer","nct":"NCT07235930","phase":"3","status":"recruiting"},{"id":"nct06733038","name":"FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.","nct":"NCT06733038","phase":"3","status":"recruiting"},{"id":"nct07362836","name":"Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU-RAS)","nct":"NCT07362836","phase":"3","status":"planned"},{"id":"nct07722494","name":"IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer","nct":"NCT07722494","phase":"3","status":"recruiting"},{"id":"nct06199973","name":"Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, ","nct":"NCT06199973","phase":"3","status":"active"},{"id":"nct06928389","name":"Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer","nct":"NCT06928389","phase":"3","status":"recruiting"},{"id":"nct07620574","name":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","nct":"NCT07620574","phase":"3","status":"recruiting"},{"id":"nct05445778","name":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal C","nct":"NCT05445778","phase":"3","status":"active"},{"id":"nct04181060","name":"Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer","nct":"NCT04181060","phase":"3","status":"recruiting"},{"id":"nct06396065","name":"Phase III Study of AK112 for NSCLC Patients","nct":"NCT06396065","phase":"3","status":"active"},{"id":"nct06921785","name":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","nct":"NCT06921785","phase":"3","status":"recruiting"},{"id":"nct03016819","name":"Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)","nct":"NCT03016819","phase":"3","status":"recruiting"},{"id":"nct06889688","name":"Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer","nct":"NCT06889688","phase":"3","status":"recruiting"},{"id":"nct06616532","name":"PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer","nct":"NCT06616532","phase":"3","status":"active"},{"id":"nct06419621","name":"PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC","nct":"NCT06419621","phase":"3","status":"active"},{"id":"nct07271355","name":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases,","nct":"NCT07271355","phase":"3","status":"planned"},{"id":"nct03172299","name":"Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma","nct":"NCT03172299","phase":"3","status":"completed"},{"id":"nct07025239","name":"QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer","nct":"NCT07025239","phase":"3","status":"planned"},{"id":"nct03828227","name":"QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.","nct":"NCT03828227","phase":"3","status":"active"},{"id":"nct05794971","name":"Regorafenib Combined With Irinotecan Drug-Eluting Beads for Colorectal Cancer Liver Metastases","nct":"NCT05794971","phase":"3","status":"recruiting"},{"id":"nct07173751","name":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","nct":"NCT07173751","phase":"3","status":"recruiting"},{"id":"nct06712355","name":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","nct":"NCT06712355","phase":"3","status":"recruiting"},{"id":"nct05043090","name":"Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC","nct":"NCT05043090","phase":"3","status":"active"},{"id":"nct07549399","name":"SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC","nct":"NCT07549399","phase":"3","status":"recruiting"},{"id":"nct06123494","name":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","nct":"NCT06123494","phase":"3","status":"recruiting"},{"id":"nct04776655","name":"Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB","nct":"NCT04776655","phase":"3","status":"active"},{"id":"nct07011719","name":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","nct":"NCT07011719","phase":"3","status":"recruiting"},{"id":"nct06584032","name":"Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer","nct":"NCT06584032","phase":"3","status":"recruiting"},{"id":"nct05239741","name":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","nct":"NCT05239741","phase":"3","status":"active"},{"id":"nct07775287","name":"Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast","nct":"NCT07775287","phase":"3","status":"recruiting"},{"id":"nct06819007","name":"Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-","nct":"NCT06819007","phase":"3","status":"recruiting"},{"id":"nct05425940","name":"Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer","nct":"NCT05425940","phase":"3","status":"active"},{"id":"nct07225270","name":"Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re","nct":"NCT07225270","phase":"3","status":"recruiting"},{"id":"nct07564141","name":"Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or","nct":"NCT07564141","phase":"3","status":"recruiting"},{"id":"nct04342910","name":"Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC","nct":"NCT04342910","phase":"3","status":"recruiting"},{"id":"nct03635021","name":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumu","nct":"NCT03635021","phase":"3","status":"active"},{"id":"nct02885753","name":"Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal C","nct":"NCT02885753","phase":"3","status":"recruiting"},{"id":"nct02997228","name":"Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study","nct":"NCT02997228","phase":"3","status":"active"},{"id":"nct07134205","name":"The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer","nct":"NCT07134205","phase":"3","status":"planned"},{"id":"nct06441344","name":"Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell","nct":"NCT06441344","phase":"3","status":"planned"},{"id":"nct07750158","name":"Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease","nct":"NCT07750158","phase":"3","status":"recruiting"},{"id":"orient-32","name":"ORIENT-32","nct":"NCT03794440","phase":"2/3","status":"positive"},{"id":"zgdh3","name":"ZGDH3 (donafenib vs sorafenib)","nct":"NCT02645981","phase":"2/3","status":"positive"},{"id":"lume-meso","name":"LUME-Meso","nct":"NCT01907100","phase":"2/3","status":"negative"},{"id":"alter-0303","name":"ALTER 0303","nct":"NCT02388919","phase":"2/3","status":"positive"},{"id":"maps","name":"MAPS","nct":"NCT00651456","phase":"2/3","status":"positive"},{"id":"geparsixto","name":"GeparSixto","nct":"NCT01426880","phase":"2/3","status":"positive"},{"id":"nct07585279","name":"A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer","nct":"NCT07585279","phase":"2/3","status":"planned"},{"id":"nct04547166","name":"A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Meta","nct":"NCT04547166","phase":"2/3","status":"recruiting"},{"id":"nct06361888","name":"A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer","nct":"NCT06361888","phase":"2/3","status":"recruiting"},{"id":"companion-002","name":"A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)","nct":"NCT05506943","phase":"2/3","status":"active"},{"id":"nct07815665","name":"A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma","nct":"NCT07815665","phase":"2/3","status":"recruiting"},{"id":"nct07221357","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Parti","nct":"NCT07221357","phase":"2/3","status":"recruiting"},{"id":"nct07221149","name":"A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)","nct":"NCT07221149","phase":"2/3","status":"recruiting"},{"id":"nct06616584","name":"Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemoth","nct":"NCT06616584","phase":"2/3","status":"recruiting"},{"id":"nct04322617","name":"Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer","nct":"NCT04322617","phase":"2/3","status":"recruiting"},{"id":"nct06662877","name":"Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment","nct":"NCT06662877","phase":"2/3","status":"planned"},{"id":"nct06123884","name":"BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer","nct":"NCT06123884","phase":"2/3","status":"recruiting"},{"id":"ea2197-ivonescimab","name":"EA2197 ivonescimab: ivonescimab with gemcitabine and cisplatin versus standard chemo-immunotherapy in advanced biliary tract cancer","nct":"NCT07765433","phase":"2/3","status":"planned"},{"id":"nct06441565","name":"Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer","nct":"NCT06441565","phase":"2/3","status":"recruiting"},{"id":"nct07718737","name":"Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Can","nct":"NCT07718737","phase":"2/3","status":"planned"},{"id":"nct06443671","name":"Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer","nct":"NCT06443671","phase":"2/3","status":"planned"},{"id":"nct06280495","name":"Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients","nct":"NCT06280495","phase":"2/3","status":"recruiting"},{"id":"nct07636226","name":"QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","nct":"NCT07636226","phase":"2/3","status":"planned"},{"id":"nct05462613","name":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","nct":"NCT05462613","phase":"2/3","status":"recruiting"},{"id":"nct06712316","name":"Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer","nct":"NCT06712316","phase":"2/3","status":"recruiting"},{"id":"nct06082167","name":"Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","nct":"NCT06082167","phase":"2/3","status":"active"},{"id":"nct05096663","name":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer","nct":"NCT05096663","phase":"2/3","status":"active"},{"id":"nct06943755","name":"Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors","nct":"NCT06943755","phase":"2/3","status":"recruiting"},{"id":"gbm-agile","name":"GBM AGILE","nct":"NCT03970447","phase":"platform","status":"recruiting"},{"id":"lung-map","name":"Lung-MAP (SWOG S1400 and S1900)","nct":"NCT02154490","phase":"platform","status":"completed"},{"id":"nci-match","name":"NCI-MATCH (EAY131)","nct":"NCT02465060","phase":"platform","status":"active"},{"id":"firstmappp","name":"FIRSTMAPPP","nct":"NCT01371201","phase":"2","status":"positive"},{"id":"intuitt-nf2","name":"INTUITT-NF2","nct":"NCT04374305","phase":"2","status":"recruiting"},{"id":"nct04373369","name":"Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","nct":"NCT04373369","phase":"2"},{"id":"lung-map-s1800a","name":"Lung-MAP S1800A: ramucirumab plus pembrolizumab","nct":"NCT03971474","phase":"2","status":"positive"},{"id":"mountaineer","name":"MOUNTAINEER","nct":"NCT03043313","phase":"2","status":"completed"},{"id":"nct02519348","name":"A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma","nct":"NCT02519348","phase":"2","status":"active"},{"id":"nct02711553","name":"A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer","nct":"NCT02711553","phase":"2","status":"active"},{"id":"papmet","name":"PAPMET (SWOG S1500)","nct":"NCT02761057","phase":"2","status":"positive"},{"id":"cabone","name":"CABONE","nct":"NCT02243605","phase":"2","status":"positive"},{"id":"tapur","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","nct":"NCT02693535","phase":"2","status":"recruiting"},{"id":"regobone","name":"REGOBONE","nct":"NCT02389244","phase":"2","status":"positive"},{"id":"herby","name":"HERBY","nct":"NCT01390948","phase":"2","status":"negative"},{"id":"nct01882868","name":"A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan","nct":"NCT01882868","phase":"2","status":"completed"},{"id":"clocc","name":"CLOCC","nct":"NCT00043004","phase":"2","status":"positive"},{"id":"calgb-40603","name":"CALGB 40603 (Alliance)","nct":"NCT00861705","phase":"2","status":"mixed"},{"id":"nct00390234","name":"Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma","nct":"NCT00390234","phase":"2","status":"completed"},{"id":"nct06856837","name":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorec","nct":"NCT06856837","phase":"2","status":"recruiting"},{"id":"nct06829355","name":"\"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer\"","nct":"NCT06829355","phase":"2","status":"recruiting"},{"id":"nct00943449","name":"4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma","nct":"NCT00943449","phase":"2","status":"completed"},{"id":"nct06887218","name":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer","nct":"NCT06887218","phase":"2","status":"recruiting"},{"id":"nct07502014","name":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line","nct":"NCT07502014","phase":"2","status":"planned"},{"id":"nct07714668","name":"A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer","nct":"NCT07714668","phase":"2","status":"recruiting"},{"id":"nct05913089","name":"A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer","nct":"NCT05913089","phase":"2","status":"recruiting"},{"id":"nct06979908","name":"A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal C","nct":"NCT06979908","phase":"2","status":"recruiting"},{"id":"nct06982924","name":"A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.","nct":"NCT06982924","phase":"2","status":"planned"},{"id":"nct06783647","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]","nct":"NCT06783647","phase":"2","status":"recruiting"},{"id":"nct07111546","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]","nct":"NCT07111546","phase":"2","status":"recruiting"},{"id":"nct07255404","name":"A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have N","nct":"NCT07255404","phase":"2","status":"recruiting"},{"id":"nct07297212","name":"A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma","nct":"NCT07297212","phase":"2","status":"recruiting"},{"id":"nct05934331","name":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","nct":"NCT05934331","phase":"2","status":"recruiting"},{"id":"nct05999994","name":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","nct":"NCT05999994","phase":"2","status":"recruiting"},{"id":"nct06936644","name":"A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation","nct":"NCT06936644","phase":"2","status":"planned"},{"id":"nct07562581","name":"A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC","nct":"NCT07562581","phase":"2","status":"recruiting"},{"id":"nct06493760","name":"A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients","nct":"NCT06493760","phase":"2","status":"recruiting"},{"id":"nct07233850","name":"A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers","nct":"NCT07233850","phase":"2","status":"planned"},{"id":"nct07229872","name":"A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer","nct":"NCT07229872","phase":"2","status":"planned"},{"id":"nct07052253","name":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.","nct":"NCT07052253","phase":"2","status":"recruiting"},{"id":"nct06218888","name":"A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Micro","nct":"NCT06218888","phase":"2","status":"planned"},{"id":"nct07679399","name":"A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.","nct":"NCT07679399","phase":"2","status":"recruiting"},{"id":"nct07669779","name":"A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer","nct":"NCT07669779","phase":"2","status":"recruiting"},{"id":"nct07474727","name":"A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer","nct":"NCT07474727","phase":"2","status":"recruiting"},{"id":"nct07071714","name":"A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer","nct":"NCT07071714","phase":"2","status":"active"},{"id":"nct07815223","name":"A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC","nct":"NCT07815223","phase":"2","status":"recruiting"},{"id":"nct06746545","name":"A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.","nct":"NCT06746545","phase":"2","status":"planned"},{"id":"nct06992258","name":"A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer","nct":"NCT06992258","phase":"2","status":"recruiting"},{"id":"nct07099794","name":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen","nct":"NCT07099794","phase":"2","status":"planned"},{"id":"nct06654947","name":"A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.","nct":"NCT06654947","phase":"2","status":"planned"},{"id":"nct07229846","name":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatme","nct":"NCT07229846","phase":"2","status":"planned"},{"id":"nct07347951","name":"A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer","nct":"NCT07347951","phase":"2","status":"recruiting"},{"id":"nct06096779","name":"A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr","nct":"NCT06096779","phase":"2","status":"active"},{"id":"nct04931342","name":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","nct":"NCT04931342","phase":"2","status":"active"},{"id":"nct05382442","name":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","nct":"NCT05382442","phase":"2","status":"active"},{"id":"nct07538271","name":"A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer","nct":"NCT07538271","phase":"2","status":"planned"},{"id":"nct07054567","name":"A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer","nct":"NCT07054567","phase":"2","status":"recruiting"},{"id":"nct06962787","name":"A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer","nct":"NCT06962787","phase":"2","status":"recruiting"},{"id":"nct07492680","name":"A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)","nct":"NCT07492680","phase":"2","status":"recruiting"},{"id":"nct07412262","name":"A Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy and Hig","nct":"NCT07412262","phase":"2","status":"recruiting"},{"id":"nct05859217","name":"A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)","nct":"NCT05859217","phase":"2","status":"planned"},{"id":"nct06246643","name":"A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies","nct":"NCT06246643","phase":"2","status":"active"},{"id":"nct07011576","name":"A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)","nct":"NCT07011576","phase":"2","status":"recruiting"},{"id":"nct07087158","name":"A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma","nct":"NCT07087158","phase":"2","status":"recruiting"},{"id":"nct05805501","name":"A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cel","nct":"NCT05805501","phase":"2","status":"active"},{"id":"nct07245446","name":"A Study of Ivonescimab in First-Line ES-SCLC","nct":"NCT07245446","phase":"2","status":"recruiting"},{"id":"nct07098338","name":"A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)","nct":"NCT07098338","phase":"2","status":"recruiting"},{"id":"nct06792695","name":"A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer","nct":"NCT06792695","phase":"2","status":"recruiting"},{"id":"nct05844150","name":"A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC","nct":"NCT05844150","phase":"2","status":"active"},{"id":"nct05879055","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With NEN","nct":"NCT05879055","phase":"2","status":"active"},{"id":"nct05879068","name":"A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC","nct":"NCT05879068","phase":"2","status":"active"},{"id":"nct07448922","name":"A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors","nct":"NCT07448922","phase":"2","status":"recruiting"},{"id":"nct06271837","name":"A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors","nct":"NCT06271837","phase":"2","status":"active"},{"id":"nct06038578","name":"A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer","nct":"NCT06038578","phase":"2","status":"recruiting"},{"id":"nct06944106","name":"A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer","nct":"NCT06944106","phase":"2","status":"recruiting"},{"id":"nct07059845","name":"A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult","nct":"NCT07059845","phase":"2","status":"recruiting"},{"id":"nct06890338","name":"A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Fo","nct":"NCT06890338","phase":"2","status":"recruiting"},{"id":"nct07024784","name":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1","nct":"NCT07024784","phase":"2","status":"recruiting"},{"id":"nct07680764","name":"A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu","nct":"NCT07680764","phase":"2","status":"recruiting"},{"id":"nct07178717","name":"A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy W","nct":"NCT07178717","phase":"2","status":"planned"},{"id":"nct06820463","name":"A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,","nct":"NCT06820463","phase":"2","status":"recruiting"},{"id":"nct06948448","name":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard ","nct":"NCT06948448","phase":"2","status":"recruiting"},{"id":"nct05954429","name":"A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-cente","nct":"NCT05954429","phase":"2","status":"recruiting"},{"id":"nct07235293","name":"A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.","nct":"NCT07235293","phase":"2","status":"recruiting"},{"id":"nct03634540","name":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)","nct":"NCT03634540","phase":"2","status":"active"},{"id":"nct06679985","name":"A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepat","nct":"NCT06679985","phase":"2","status":"active"},{"id":"nct06895928","name":"A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors","nct":"NCT06895928","phase":"2","status":"recruiting"},{"id":"nct06040099","name":"A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat","nct":"NCT06040099","phase":"2","status":"active"},{"id":"nct06475209","name":"Adebrelimab + Apatinib in SCLC Maintenance Therapy","nct":"NCT06475209","phase":"2","status":"recruiting"},{"id":"nct07767994","name":"AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer","nct":"NCT07767994","phase":"2","status":"planned"},{"id":"nct07158840","name":"AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor","nct":"NCT07158840","phase":"2","status":"planned"},{"id":"nct05247684","name":"AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC","nct":"NCT05247684","phase":"2","status":"active"},{"id":"nct07021950","name":"AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer","nct":"NCT07021950","phase":"2","status":"planned"},{"id":"nct05192798","name":"Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC","nct":"NCT05192798","phase":"2","status":"recruiting"},{"id":"nct07130903","name":"Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer","nct":"NCT07130903","phase":"2","status":"recruiting"},{"id":"nct07282262","name":"An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.","nct":"NCT07282262","phase":"2","status":"recruiting"},{"id":"nct06560112","name":"An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer","nct":"NCT06560112","phase":"2","status":"recruiting"},{"id":"nct02955940","name":"An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib","nct":"NCT02955940","phase":"2","status":"active"},{"id":"nct07398326","name":"Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer","nct":"NCT07398326","phase":"2","status":"recruiting"},{"id":"nct07635290","name":"Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer","nct":"NCT07635290","phase":"2","status":"active"},{"id":"nct07071844","name":"BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients","nct":"NCT07071844","phase":"2","status":"planned"},{"id":"nct07722754","name":"Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial","nct":"NCT07722754","phase":"2","status":"recruiting"},{"id":"nct01639508","name":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or A","nct":"NCT01639508","phase":"2","status":"recruiting"},{"id":"nct06168786","name":"Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC","nct":"NCT06168786","phase":"2","status":"recruiting"},{"id":"nct06901622","name":"Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma","nct":"NCT06901622","phase":"2","status":"recruiting"},{"id":"nct06881537","name":"CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer","nct":"NCT06881537","phase":"2","status":"recruiting"},{"id":"nct07383285","name":"CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal C","nct":"NCT07383285","phase":"2","status":"planned"},{"id":"nct07125391","name":"Chemotherapy Combined With Propranolol Hydrochloride as Neoadjuvant Therapy for Advanced High-grade Serous Ovarian Cancer","nct":"NCT07125391","phase":"2","status":"recruiting"},{"id":"nct05190445","name":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma","nct":"NCT05190445","phase":"2","status":"active"},{"id":"nct06992336","name":"Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy","nct":"NCT06992336","phase":"2","status":"recruiting"},{"id":"nct06540326","name":"Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab","nct":"NCT06540326","phase":"2","status":"recruiting"},{"id":"nct06767813","name":"Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms","nct":"NCT06767813","phase":"2","status":"recruiting"},{"id":"nct07548177","name":"Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma","nct":"NCT07548177","phase":"2","status":"recruiting"},{"id":"nct03919461","name":"Colorectal Metastasis Prevention International Trial 2","nct":"NCT03919461","phase":"2","status":"recruiting"},{"id":"nct05757336","name":"Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer","nct":"NCT05757336","phase":"2","status":"recruiting"},{"id":"nct06411600","name":"Combination Therapy for BRAF-V600E Metastatic CRCm","nct":"NCT06411600","phase":"2","status":"recruiting"},{"id":"nct06686030","name":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","nct":"NCT06686030","phase":"2","status":"recruiting"},{"id":"nct03937830","name":"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","nct":"NCT03937830","phase":"2","status":"active"},{"id":"nct07829874","name":"Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.","nct":"NCT07829874","phase":"2","status":"planned"},{"id":"nct05057052","name":"Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis","nct":"NCT05057052","phase":"2","status":"recruiting"},{"id":"nct06951646","name":"ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)","nct":"NCT06951646","phase":"2","status":"recruiting"},{"id":"nct06953089","name":"DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors","nct":"NCT06953089","phase":"2","status":"recruiting"},{"id":"nct07159217","name":"Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer","nct":"NCT07159217","phase":"2","status":"planned"},{"id":"nct07081633","name":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma","nct":"NCT07081633","phase":"2","status":"active"},{"id":"nct06276283","name":"DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)","nct":"NCT06276283","phase":"2","status":"recruiting"},{"id":"nct06282445","name":"Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsate","nct":"NCT06282445","phase":"2","status":"recruiting"},{"id":"nct06949982","name":"Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Co","nct":"NCT06949982","phase":"2","status":"recruiting"},{"id":"nct06028633","name":"Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients","nct":"NCT06028633","phase":"2","status":"planned"},{"id":"nct07728019","name":"Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM","nct":"NCT07728019","phase":"2","status":"recruiting"},{"id":"nct05364489","name":"Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer","nct":"NCT05364489","phase":"2","status":"planned"},{"id":"nct06643793","name":"Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC","nct":"NCT06643793","phase":"2","status":"recruiting"},{"id":"nct07787429","name":"Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma","nct":"NCT07787429","phase":"2","status":"recruiting"},{"id":"nct06607458","name":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatme","nct":"NCT06607458","phase":"2","status":"recruiting"},{"id":"nct06145074","name":"Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.","nct":"NCT06145074","phase":"2","status":"recruiting"},{"id":"nct07007767","name":"Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）","nct":"NCT07007767","phase":"2","status":"planned"},{"id":"nct07446322","name":"FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer","nct":"NCT07446322","phase":"2","status":"recruiting"},{"id":"nct05727163","name":"FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutat","nct":"NCT05727163","phase":"2","status":"recruiting"},{"id":"nct07621497","name":"FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)","nct":"NCT07621497","phase":"2","status":"planned"},{"id":"nct06484153","name":"Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma","nct":"NCT06484153","phase":"2","status":"recruiting"},{"id":"nct07510932","name":"Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)","nct":"NCT07510932","phase":"2","status":"planned"},{"id":"nct07724223","name":"Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC","nct":"NCT07724223","phase":"2","status":"recruiting"},{"id":"nct07051785","name":"Fruquintinib vs Bevacizumab Combined With Irinotecan Liposome and Capecitabine as Second-Line Therapy for Advanced Metastatic Colorectal Cancer","nct":"NCT07051785","phase":"2","status":"planned"},{"id":"nct06563986","name":"FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer","nct":"NCT06563986","phase":"2","status":"recruiting"},{"id":"nct05334277","name":"Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA","nct":"NCT05334277","phase":"2","status":"recruiting"},{"id":"nct06963060","name":"Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)","nct":"NCT06963060","phase":"2","status":"recruiting"},{"id":"nct06558773","name":"GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.","nct":"NCT06558773","phase":"2","status":"recruiting"},{"id":"nct06389500","name":"HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer","nct":"NCT06389500","phase":"2","status":"planned"},{"id":"nct06849492","name":"HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer","nct":"NCT06849492","phase":"2","status":"planned"},{"id":"nct07183865","name":"Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)","nct":"NCT07183865","phase":"2","status":"recruiting"},{"id":"nct06928584","name":"Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer","nct":"NCT06928584","phase":"2","status":"recruiting"},{"id":"nct06787612","name":"Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer","nct":"NCT06787612","phase":"2","status":"recruiting"},{"id":"nct07263360","name":"Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","nct":"NCT07263360","phase":"2","status":"planned"},{"id":"nct07007728","name":"Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis","nct":"NCT07007728","phase":"2","status":"planned"},{"id":"nct07405190","name":"Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC","nct":"NCT07405190","phase":"2","status":"recruiting"},{"id":"nct06993025","name":"Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies","nct":"NCT06993025","phase":"2","status":"planned"},{"id":"nct06848842","name":"Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases","nct":"NCT06848842","phase":"2","status":"recruiting"},{"id":"nct06991491","name":"Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)","nct":"NCT06991491","phase":"2","status":"planned"},{"id":"nct06491472","name":"Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Pancreatic Cancer","nct":"NCT06491472","phase":"2","status":"recruiting"},{"id":"nct07503756","name":"JS212 Combination Therapies in Metastatic Colorectal Cancer","nct":"NCT07503756","phase":"2","status":"recruiting"},{"id":"nct05985109","name":"KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer","nct":"NCT05985109","phase":"2","status":"recruiting"},{"id":"nct05170438","name":"Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment","nct":"NCT05170438","phase":"2","status":"active"},{"id":"nct06192680","name":"Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer","nct":"NCT06192680","phase":"2","status":"planned"},{"id":"nct06184698","name":"Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer","nct":"NCT06184698","phase":"2","status":"recruiting"},{"id":"nct05854498","name":"Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer","nct":"NCT05854498","phase":"2","status":"recruiting"},{"id":"nct06061809","name":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","nct":"NCT06061809","phase":"2","status":"active"},{"id":"nct07743632","name":"Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC","nct":"NCT07743632","phase":"2","status":"planned"},{"id":"nct06790212","name":"Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer","nct":"NCT06790212","phase":"2","status":"planned"},{"id":"nct07351487","name":"Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)","nct":"NCT07351487","phase":"2","status":"recruiting"},{"id":"nct07549906","name":"Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospecti","nct":"NCT07549906","phase":"2","status":"planned"},{"id":"nct06718543","name":"Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer","nct":"NCT06718543","phase":"2","status":"recruiting"},{"id":"nct07134101","name":"Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer (SMARTi-RC01)","nct":"NCT07134101","phase":"2","status":"planned"},{"id":"nct06977542","name":"Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer","nct":"NCT06977542","phase":"2","status":"planned"},{"id":"nct07559760","name":"New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer","nct":"NCT07559760","phase":"2","status":"recruiting"},{"id":"nct07677579","name":"NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer","nct":"NCT07677579","phase":"2","status":"planned"},{"id":"nct07674732","name":"Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer","nct":"NCT07674732","phase":"2","status":"recruiting"},{"id":"nct06919848","name":"Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)","nct":"NCT06919848","phase":"2","status":"planned"},{"id":"nct06764680","name":"Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer","nct":"NCT06764680","phase":"2","status":"recruiting"},{"id":"nct07001618","name":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiot","nct":"NCT07001618","phase":"2","status":"recruiting"},{"id":"nct07819591","name":"Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC","nct":"NCT07819591","phase":"2","status":"planned"},{"id":"nct03899155","name":"Pan Tumor Rollover Study","nct":"NCT03899155","phase":"2","status":"recruiting"},{"id":"nct06976944","name":"Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer","nct":"NCT06976944","phase":"2","status":"recruiting"},{"id":"nct05903833","name":"Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surge","nct":"NCT05903833","phase":"2","status":"recruiting"},{"id":"nct04976634","name":"Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)","nct":"NCT04976634","phase":"2","status":"active"},{"id":"nct06230471","name":"Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer","nct":"NCT06230471","phase":"2","status":"recruiting"},{"id":"nct04846634","name":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (A","nct":"NCT04846634","phase":"2","status":"planned"},{"id":"nct07353268","name":"Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerabil","nct":"NCT07353268","phase":"2","status":"planned"},{"id":"nct06852287","name":"Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer","nct":"NCT06852287","phase":"2","status":"recruiting"},{"id":"nct06708858","name":"Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer","nct":"NCT06708858","phase":"2","status":"recruiting"},{"id":"nct06959550","name":"Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer","nct":"NCT06959550","phase":"2","status":"recruiting"},{"id":"nct07530445","name":"Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer","nct":"NCT07530445","phase":"2","status":"recruiting"},{"id":"nct06341296","name":"Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer","nct":"NCT06341296","phase":"2","status":"recruiting"},{"id":"nct07670273","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer","nct":"NCT07670273","phase":"2","status":"recruiting"},{"id":"nct07704177","name":"Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer","nct":"NCT07704177","phase":"2","status":"recruiting"},{"id":"nct07234877","name":"Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets","nct":"NCT07234877","phase":"2","status":"planned"},{"id":"nct07017673","name":"Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer","nct":"NCT07017673","phase":"2","status":"recruiting"},{"id":"nct07310173","name":"Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma","nct":"NCT07310173","phase":"2","status":"recruiting"},{"id":"nct07133750","name":"PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer","nct":"NCT07133750","phase":"2","status":"recruiting"},{"id":"nct05741164","name":"Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer","nct":"NCT05741164","phase":"2","status":"recruiting"},{"id":"nct07103447","name":"Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC","nct":"NCT07103447","phase":"2","status":"planned"},{"id":"nct06788171","name":"PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM","nct":"NCT06788171","phase":"2","status":"planned"},{"id":"nct06892925","name":"QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors","nct":"NCT06892925","phase":"2","status":"active"},{"id":"nct07009145","name":"QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC","nct":"NCT07009145","phase":"2","status":"planned"},{"id":"nct06786026","name":"QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC","nct":"NCT06786026","phase":"2","status":"recruiting"},{"id":"nct07110064","name":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","nct":"NCT07110064","phase":"2","status":"recruiting"},{"id":"nct07601178","name":"QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride","nct":"NCT07601178","phase":"2","status":"recruiting"},{"id":"nct07116577","name":"Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC","nct":"NCT07116577","phase":"2","status":"planned"},{"id":"nct06911684","name":"Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.","nct":"NCT06911684","phase":"2","status":"recruiting"},{"id":"nct07071961","name":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di","nct":"NCT07071961","phase":"2","status":"recruiting"},{"id":"nct05963490","name":"Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","nct":"NCT05963490","phase":"2","status":"recruiting"},{"id":"nct06425133","name":"Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers","nct":"NCT06425133","phase":"2","status":"recruiting"},{"id":"nct06906341","name":"Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers","nct":"NCT06906341","phase":"2","status":"recruiting"},{"id":"nct07773363","name":"Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic Cancer","nct":"NCT07773363","phase":"2","status":"planned"},{"id":"nct07381764","name":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\"","nct":"NCT07381764","phase":"2","status":"recruiting"},{"id":"nct07623577","name":"Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases","nct":"NCT07623577","phase":"2","status":"recruiting"},{"id":"nct06401824","name":"Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases","nct":"NCT06401824","phase":"2","status":"recruiting"},{"id":"nct07359404","name":"Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC","nct":"NCT07359404","phase":"2","status":"recruiting"},{"id":"nct07501169","name":"Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","nct":"NCT07501169","phase":"2","status":"planned"},{"id":"nct06685276","name":"Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer","nct":"NCT06685276","phase":"2","status":"recruiting"},{"id":"nct07150247","name":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","nct":"NCT07150247","phase":"2","status":"recruiting"},{"id":"nct06841055","name":"Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che","nct":"NCT06841055","phase":"2","status":"recruiting"},{"id":"nct06245356","name":"Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer","nct":"NCT06245356","phase":"2","status":"recruiting"},{"id":"nct06835179","name":"SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.","nct":"NCT06835179","phase":"2","status":"planned"},{"id":"nct07535632","name":"SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer","nct":"NCT07535632","phase":"2","status":"planned"},{"id":"nct07162714","name":"SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer","nct":"NCT07162714","phase":"2","status":"recruiting"},{"id":"nct07150403","name":"Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal","nct":"NCT07150403","phase":"2","status":"planned"},{"id":"nct06856187","name":"Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer","nct":"NCT06856187","phase":"2","status":"recruiting"},{"id":"nct07025174","name":"Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer","nct":"NCT07025174","phase":"2","status":"recruiting"},{"id":"nct05806931","name":"Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer","nct":"NCT05806931","phase":"2","status":"recruiting"},{"id":"nct07819604","name":"Serplulimab Combined With CAPOX and Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer","nct":"NCT07819604","phase":"2","status":"planned"},{"id":"sevilla","name":"SEVILLA","nct":"NCT06529718","phase":"2","status":"recruiting"},{"id":"nct06872606","name":"Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for","nct":"NCT06872606","phase":"2","status":"planned"},{"id":"nct06802666","name":"Short-course Radiotherapy Followed by AK112 and CAPOX as Neoadjuvant Therapy for Locally Advanced Rectal Cancer","nct":"NCT06802666","phase":"2","status":"recruiting"},{"id":"nct07005570","name":"Short-course Radiotherapy Followed by Sequential Chemotherapy With or Without PD-1 Monoclonal Antibody and Bevacizumab as Total Neoadjuvant Therapy in pMMR/MSS","nct":"NCT07005570","phase":"2","status":"recruiting"},{"id":"nct07515820","name":"SHR-3821 in Advanced Colorectal Cancer: an Exploratory Study","nct":"NCT07515820","phase":"2","status":"planned"},{"id":"nct06465563","name":"SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer","nct":"NCT06465563","phase":"2","status":"active"},{"id":"nct07213570","name":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","nct":"NCT07213570","phase":"2","status":"recruiting"},{"id":"nct05588388","name":"Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases","nct":"NCT05588388","phase":"2","status":"recruiting"},{"id":"nct05447702","name":"Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)","nct":"NCT05447702","phase":"2","status":"recruiting"},{"id":"nct05489211","name":"Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)","nct":"NCT05489211","phase":"2","status":"recruiting"},{"id":"nct07527858","name":"Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer","nct":"NCT07527858","phase":"2","status":"recruiting"},{"id":"nct05112991","name":"Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer","nct":"NCT05112991","phase":"2","status":"recruiting"},{"id":"nct05775159","name":"Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer","nct":"NCT05775159","phase":"2","status":"active"},{"id":"nct06106308","name":"Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab fo","nct":"NCT06106308","phase":"2","status":"active"},{"id":"nct07638852","name":"Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.","nct":"NCT07638852","phase":"2","status":"recruiting"},{"id":"nct05733598","name":"Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC","nct":"NCT05733598","phase":"2","status":"recruiting"},{"id":"nct06558227","name":"Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma","nct":"NCT06558227","phase":"2","status":"recruiting"},{"id":"nct06107413","name":"Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unrese","nct":"NCT06107413","phase":"2","status":"active"},{"id":"nct05822752","name":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Bu","nct":"NCT05822752","phase":"2","status":"active"},{"id":"nct05988372","name":"Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)","nct":"NCT05988372","phase":"2","status":"planned"},{"id":"nct06531291","name":"Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation","nct":"NCT06531291","phase":"2","status":"planned"},{"id":"nct07469956","name":"Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer","nct":"NCT07469956","phase":"2","status":"planned"},{"id":"nct06293014","name":"TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer","nct":"NCT06293014","phase":"2","status":"recruiting"},{"id":"nct04701476","name":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","nct":"NCT04701476","phase":"2","status":"recruiting"},{"id":"nct07359456","name":"Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases","nct":"NCT07359456","phase":"2","status":"planned"},{"id":"nct05628038","name":"The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer","nct":"NCT05628038","phase":"2","status":"recruiting"},{"id":"nct06092242","name":"The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer","nct":"NCT06092242","phase":"2","status":"planned"},{"id":"nct06125080","name":"The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospec","nct":"NCT06125080","phase":"2","status":"recruiting"},{"id":"nct07662031","name":"Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer","nct":"NCT07662031","phase":"2","status":"planned"},{"id":"nct04875585","name":"Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC","nct":"NCT04875585","phase":"2","status":"recruiting"},{"id":"nct05007132","name":"Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer","nct":"NCT05007132","phase":"2","status":"recruiting"},{"id":"nct07407465","name":"Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.","nct":"NCT07407465","phase":"2","status":"recruiting"},{"id":"nct06683703","name":"Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases","nct":"NCT06683703","phase":"2","status":"planned"},{"id":"nct07219459","name":"Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)","nct":"NCT07219459","phase":"2","status":"recruiting"},{"id":"nct05771181","name":"Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients","nct":"NCT05771181","phase":"2","status":"recruiting"},{"id":"nct06448754","name":"Volrustomig Priming Regimens Exploratory Phase II Platform Study","nct":"NCT06448754","phase":"2","status":"active"},{"id":"nct07047001","name":"Vorolanib Monotherapy or in Combination With Toripalimab as Adjuvant Therapy for Patients With Intermediate-high Risk of Recurrence in Renal Cell Carcinoma","nct":"NCT07047001","phase":"2","status":"active"},{"id":"nct06523049","name":"Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy","nct":"NCT06523049","phase":"2","status":"planned"},{"id":"nct02734004","name":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","nct":"NCT02734004","phase":"1/2","status":"active"},{"id":"nct02671435","name":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors","nct":"NCT02671435","phase":"1/2","status":"active"},{"id":"nct04068610","name":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC","nct":"NCT04068610","phase":"1/2","status":"active"},{"id":"nct04689347","name":"5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.","nct":"NCT04689347","phase":"1/2","status":"recruiting"},{"id":"nct06843447","name":"A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","nct":"NCT06843447","phase":"1/2","status":"recruiting"},{"id":"nct06840002","name":"A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer","nct":"NCT06840002","phase":"1/2","status":"recruiting"},{"id":"nct06827236","name":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","nct":"NCT06827236","phase":"1/2","status":"recruiting"},{"id":"nct06892548","name":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","nct":"NCT06892548","phase":"1/2","status":"recruiting"},{"id":"nct07079631","name":"A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT3","nct":"NCT07079631","phase":"1/2","status":"recruiting"},{"id":"nct07070232","name":"A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors","nct":"NCT07070232","phase":"1/2","status":"recruiting"},{"id":"nct07653685","name":"A Clinical Trial Evaluating TQB2930 Injection and Chemotherapy With or Without Bevacizumab in Patients With HER2-Abnormally Expressed Unresectable Locally Advan","nct":"NCT07653685","phase":"1/2","status":"recruiting"},{"id":"nct07791758","name":"A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma","nct":"NCT07791758","phase":"1/2","status":"planned"},{"id":"nct07111520","name":"A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced ","nct":"NCT07111520","phase":"1/2","status":"recruiting"},{"id":"nct05584670","name":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","nct":"NCT05584670","phase":"1/2","status":"recruiting"},{"id":"nct07147348","name":"A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors","nct":"NCT07147348","phase":"1/2","status":"recruiting"},{"id":"nct07591597","name":"A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus F","nct":"NCT07591597","phase":"1/2","status":"planned"},{"id":"nct06427941","name":"A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol","nct":"NCT06427941","phase":"1/2","status":"recruiting"},{"id":"nct07160725","name":"A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors","nct":"NCT07160725","phase":"1/2","status":"recruiting"},{"id":"nct06682780","name":"A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours","nct":"NCT06682780","phase":"1/2","status":"recruiting"},{"id":"nct06953323","name":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","nct":"NCT06953323","phase":"1/2","status":"recruiting"},{"id":"nct07040228","name":"A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer","nct":"NCT07040228","phase":"1/2","status":"recruiting"},{"id":"nct05846867","name":"A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer","nct":"NCT05846867","phase":"1/2","status":"active"},{"id":"nct07621159","name":"A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer","nct":"NCT07621159","phase":"1/2","status":"planned"},{"id":"nct07750041","name":"A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer","nct":"NCT07750041","phase":"1/2","status":"planned"},{"id":"nct07283367","name":"A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.","nct":"NCT07283367","phase":"1/2","status":"recruiting"},{"id":"nct07269158","name":"A Phase IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Maintenance Therapy in Patients With Advanced Biliary Tract Cancer","nct":"NCT07269158","phase":"1/2","status":"planned"},{"id":"nct06996782","name":"A Platform Study in Non-Small Cell Lung Cancer (NSCLC)","nct":"NCT06996782","phase":"1/2","status":"recruiting"},{"id":"nct04524871","name":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li","nct":"NCT04524871","phase":"1/2","status":"active"},{"id":"nct03424005","name":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","nct":"NCT03424005","phase":"1/2","status":"recruiting"},{"id":"nct07244705","name":"A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC","nct":"NCT07244705","phase":"1/2","status":"recruiting"},{"id":"nct07357220","name":"A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases","nct":"NCT07357220","phase":"1/2","status":"planned"},{"id":"nct06530251","name":"A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)","nct":"NCT06530251","phase":"1/2","status":"recruiting"},{"id":"nct07623356","name":"A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer","nct":"NCT07623356","phase":"1/2","status":"recruiting"},{"id":"nct05867420","name":"A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.","nct":"NCT05867420","phase":"1/2","status":"recruiting"},{"id":"nct04895709","name":"A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","nct":"NCT04895709","phase":"1/2","status":"recruiting"},{"id":"nct06697197","name":"A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors","nct":"NCT06697197","phase":"1/2","status":"recruiting"},{"id":"nct06730750","name":"A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors","nct":"NCT06730750","phase":"1/2","status":"active"},{"id":"nct04008797","name":"A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor","nct":"NCT04008797","phase":"1/2","status":"active"},{"id":"nct07805551","name":"A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer","nct":"NCT07805551","phase":"1/2","status":"recruiting"},{"id":"nct07535437","name":"A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer","nct":"NCT07535437","phase":"1/2","status":"recruiting"},{"id":"nct07535463","name":"A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer","nct":"NCT07535463","phase":"1/2","status":"recruiting"},{"id":"nct07042802","name":"A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer","nct":"NCT07042802","phase":"1/2","status":"recruiting"},{"id":"nct06796907","name":"A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)","nct":"NCT06796907","phase":"1/2","status":"recruiting"},{"id":"nct07737600","name":"A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer","nct":"NCT07737600","phase":"1/2","status":"planned"},{"id":"nct05918133","name":"A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC","nct":"NCT05918133","phase":"1/2","status":"active"},{"id":"nct06016062","name":"A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors","nct":"NCT06016062","phase":"1/2","status":"recruiting"},{"id":"nct07602855","name":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)","nct":"NCT07602855","phase":"1/2","status":"recruiting"},{"id":"nct06703177","name":"A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors","nct":"NCT06703177","phase":"1/2","status":"recruiting"},{"id":"nct05440708","name":"A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma","nct":"NCT05440708","phase":"1/2","status":"recruiting"},{"id":"nct07208773","name":"A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors","nct":"NCT07208773","phase":"1/2","status":"recruiting"},{"id":"nct07325136","name":"A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung ","nct":"NCT07325136","phase":"1/2","status":"recruiting"},{"id":"nct05319730","name":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","nct":"NCT05319730","phase":"1/2","status":"recruiting"},{"id":"nct05824975","name":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu","nct":"NCT05824975","phase":"1/2","status":"recruiting"},{"id":"nct07291076","name":"A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unres","nct":"NCT07291076","phase":"1/2","status":"recruiting"},{"id":"nct04300556","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types","nct":"NCT04300556","phase":"1/2","status":"recruiting"},{"id":"nct07293351","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal ","nct":"NCT07293351","phase":"1/2","status":"recruiting"},{"id":"nct06618287","name":"A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors","nct":"NCT06618287","phase":"1/2","status":"recruiting"},{"id":"nct06512051","name":"A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer","nct":"NCT06512051","phase":"1/2","status":"recruiting"},{"id":"nct04626635","name":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","nct":"NCT04626635","phase":"1/2","status":"active"},{"id":"nct06844422","name":"Adapted Guided Stereotactic Body Radiotherapy Combined With Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND)","nct":"NCT06844422","phase":"1/2","status":"recruiting"},{"id":"nct05405595","name":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","nct":"NCT05405595","phase":"1/2","status":"recruiting"},{"id":"nct05904379","name":"AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer","nct":"NCT05904379","phase":"1/2","status":"active"},{"id":"nct06646055","name":"AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer","nct":"NCT06646055","phase":"1/2","status":"active"},{"id":"nct07551778","name":"Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors","nct":"NCT07551778","phase":"1/2","status":"planned"},{"id":"nct07590531","name":"AMT-116 in Combination With AK112 in Patients With Lung Cancer","nct":"NCT07590531","phase":"1/2","status":"recruiting"},{"id":"nct05019690","name":"Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer","nct":"NCT05019690","phase":"1/2","status":"recruiting"},{"id":"nct05000294","name":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types","nct":"NCT05000294","phase":"1/2","status":"recruiting"},{"id":"nct03539822","name":"Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies","nct":"NCT03539822","phase":"1/2","status":"recruiting"},{"id":"nct07012954","name":"ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC","nct":"NCT07012954","phase":"1/2","status":"recruiting"},{"id":"nct04645160","name":"Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers","nct":"NCT04645160","phase":"1/2","status":"recruiting"},{"id":"nct06877650","name":"First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors","nct":"NCT06877650","phase":"1/2","status":"recruiting"},{"id":"nct05438329","name":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors","nct":"NCT05438329","phase":"1/2","status":"active"},{"id":"nct05919264","name":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","nct":"NCT05919264","phase":"1/2","status":"recruiting"},{"id":"nct04977453","name":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","nct":"NCT04977453","phase":"1/2","status":"recruiting"},{"id":"nct04121455","name":"Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients","nct":"NCT04121455","phase":"1/2","status":"active"},{"id":"nct06980532","name":"Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer","nct":"NCT06980532","phase":"1/2","status":"recruiting"},{"id":"nct07802184","name":"GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC","nct":"NCT07802184","phase":"1/2","status":"planned"},{"id":"nct07636798","name":"Hepatic Arterial Infusion Chemotherapy Plus Envafolimab and Lenvatinib for First-Line Unresectable Advanced Biliary Tract Cancer","nct":"NCT07636798","phase":"1/2","status":"recruiting"},{"id":"nct06782685","name":"Liposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV","nct":"NCT06782685","phase":"1/2","status":"recruiting"},{"id":"nct07391566","name":"LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation","nct":"NCT07391566","phase":"1/2","status":"planned"},{"id":"nct06761027","name":"mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer","nct":"NCT06761027","phase":"1/2","status":"recruiting"},{"id":"nct07479485","name":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","nct":"NCT07479485","phase":"1/2","status":"recruiting"},{"id":"nct06873763","name":"Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer","nct":"NCT06873763","phase":"1/2","status":"recruiting"},{"id":"nct04938583","name":"Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer","nct":"NCT04938583","phase":"1/2","status":"active"},{"id":"nct05797168","name":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","nct":"NCT05797168","phase":"1/2","status":"recruiting"},{"id":"nct05024214","name":"Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors","nct":"NCT05024214","phase":"1/2","status":"recruiting"},{"id":"nct05739981","name":"Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer","nct":"NCT05739981","phase":"1/2","status":"recruiting"},{"id":"nct05918445","name":"PM8002 in the Treatment of Patients With Advanced Solid Tumors","nct":"NCT05918445","phase":"1/2","status":"recruiting"},{"id":"nct07453394","name":"QLS5132 Combination Therapy in Advanced Solid Tumors","nct":"NCT07453394","phase":"1/2","status":"planned"},{"id":"nct05101070","name":"S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors","nct":"NCT05101070","phase":"1/2","status":"recruiting"},{"id":"nct07139470","name":"Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer","nct":"NCT07139470","phase":"1/2","status":"planned"},{"id":"nct06771622","name":"Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors","nct":"NCT06771622","phase":"1/2","status":"active"},{"id":"nct04262466","name":"Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors","nct":"NCT04262466","phase":"1/2","status":"active"},{"id":"nct06047379","name":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","nct":"NCT06047379","phase":"1/2","status":"recruiting"},{"id":"nct04938817","name":"Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)","nct":"NCT04938817","phase":"1/2","status":"active"},{"id":"nct06635785","name":"Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors","nct":"NCT06635785","phase":"1/2","status":"recruiting"},{"id":"nct06859775","name":"SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer","nct":"NCT06859775","phase":"1/2","status":"recruiting"},{"id":"nct02861573","name":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","nct":"NCT02861573","phase":"1/2","status":"active"},{"id":"nct07397338","name":"Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors","nct":"NCT07397338","phase":"1/2","status":"recruiting"},{"id":"nct06445062","name":"Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors","nct":"NCT06445062","phase":"1/2","status":"recruiting"},{"id":"nct05565417","name":"Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas","nct":"NCT05565417","phase":"1/2","status":"active"},{"id":"nct07080216","name":"Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer","nct":"NCT07080216","phase":"1/2","status":"recruiting"},{"id":"nct04626479","name":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","nct":"NCT04626479","phase":"1/2","status":"active"},{"id":"nct04626518","name":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","nct":"NCT04626518","phase":"1/2","status":"active"},{"id":"nct07049926","name":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (","nct":"NCT07049926","phase":"1/2","status":"recruiting"},{"id":"nct06445972","name":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","nct":"NCT06445972","phase":"1/2","status":"recruiting"},{"id":"nct07227415","name":"Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With ","nct":"NCT07227415","phase":"1/2","status":"recruiting"},{"id":"nct07472647","name":"SYS6090 Combination Therapy in Advanced Lung Cancer","nct":"NCT07472647","phase":"1/2","status":"planned"},{"id":"nct06140576","name":"The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breas","nct":"NCT06140576","phase":"1/2","status":"planned"},{"id":"nct07204574","name":"The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuxi","nct":"NCT07204574","phase":"1/2","status":"recruiting"},{"id":"nct04781192","name":"The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers","nct":"NCT04781192","phase":"1/2","status":"active"},{"id":"nct07681297","name":"Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Dis","nct":"NCT07681297","phase":"1/2","status":"planned"},{"id":"nct06456138","name":"Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC","nct":"NCT06456138","phase":"1/2","status":"planned"}],"pathways":["bladder-cancer-signalling","immune-desert-exclusion","hepatocellular-carcinoma-signalling","intravasation-ctc-survival","myeloid-suppression-axis","renal-cell-carcinoma-signalling","angiogenic-switch","cancer-immunity-cycle","pre-metastatic-niche","tumor-microenvironment","vegf-angiogenesis","hif-vhl"],"companies":["akeso","astrazeneca","aveo","bayer","betta","biocon-biologics","biontech","boehringer-ingelheim","chipscreen","compass-therapeutics","eisai","elevar-therapeutics","eli-lilly","exelixis","hetero","hutchmed","ipsen","hengrui","merck","natco","novartis","oncoc4","pfizer","pierre-fabre","regeneron","roche-genentech","sanofi","sino-biopharm","summit-therapeutics","zelgen","takeda"],"keyPapers":["paper-harmoni-2-lancet-2025","paper-dasari-fresco-2-fruquintinib-lancet-2023","paper-paradigm-jama-2023","paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023","paper-clear-nejm-2021","paper-imbrave150-nejm-2020","paper-lenz-cms-calgb-swog-80405-jco-2019","paper-paola-1-nejm-2019","paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017","paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017","paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015","paper-heinemann-fire-3-cetuximab-vs-bevacizumab-lancet-oncol-2014","paper-grothey-correct-regorafenib-lancet-2013","paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006","paper-hurwitz-bevacizumab-crc-nejm-2004"],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[{"class":"pd1-blockade","mechanism":"Immunosuppressive myeloid cells and VEGF","category":"immune-evasion"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}